# A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)

> **NCT07501559** · PHASE1,PHASE2 · RECRUITING · sponsor: **Jecho Biopharmaceuticals Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Recurrent Glioblastoma Multiforme(GBM)

## Interventions

- **BIOLOGICAL:** JL15003Injection

## Key facts

- **NCT ID:** NCT07501559
- **Lead sponsor:** Jecho Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2030-04
- **Final completion:** 2030-04
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07501559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07501559, "A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07501559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*